GlycoMira Therapeutics is a preclinical-stage biopharmaceutical company based in Salt Lake City, UT, dedicated to transforming cancer therapy and improving patient outcomes. Their innovative approach involves developing innate immune system modulators based on naturally occurring polysaccharides within the body.
With a deep commitment to scientific integrity and dedicated perseverance, GlycoMira's team is focused on developing their lead drug candidate, GM-1111, which has shown promising potential in addressing unmet needs in solid tumor treatment and supportive care. Supported by grant awards from the National Institutes of Health and private investments, GlycoMira aims to revolutionize the treatment of cancer and other inflammatory diseases.
Generated from the website